Current research on angiogenesis being conducted by Dr. Dana includes studying topical treatments of Avastin, Lucentis and anti-inflammatory medication to treat Corneal Neovascularization.
Corneal neovascularization (abnormal growth of blood vessels) can compromise your vision. Corneal neovascularization is a result of numerous diseases of the cornea such as inflammation, infection, degeneration, trauma, or corneal stem cell deficiency. This major ocular complication can lead to corneal scarring, edema, lipid deposition, and inflammation that may significantly alter visual acuity. In addition, it worsens the prognosis of subsequent corneal transplant, a treatment that many patients with severe corneal disease may ultimately need.
Common treatments for corneal neovascularization include medications such as steroids or non-steroidal anti-inflammatory agents, laser photocoagulation, fine-needle diathermy, photodynamic therapy or restoration of the ocular surface with the use of conjunctival, limbal, or amniotic membrane transplantation.
Current Clinical Trials
Our current studies include using topical Avastin, Lucentis and other anti-inflammatory medication to reduce the size of the abnormal blood vessels on the cornea. Patients participating in these studies are given the study medication at no cost and are asked to return for follow up over the course of 4 to 12 months. Corneal photographs are taken of patient’s eyes at each visit for comparission and are used to measure the reduction in size of the blood vessels.
Preliminary results of the topical Avastin study have been published in the Archives of Ophthalmology in April 2009. The results have shown that topical Avastin can significantly reduce the blood vessels in the cornea.
If you would like more information on Dr. Dana’s clinical research with corneal angiogenesis please contact Whitney Howe at 617-391-5894 or Whitney_Howe@meei.harvard.edu